The Pharma Data

JANUARY 20, 2021

Statistician: Dr. George Wells – Professor, School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa and Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute. Bennett is a board-certified cardiologist and board-eligible in critical care medicine.

Trials 52

Trials Cardiology Containment Development 52

The Pharma Data

MARCH 31, 2023

The trial was conducted in 30 countries and 105 clinical sites across North America, Europe, Asia and Latin America 3. About our longstanding commitment to heart failure Our goal is to reimagine medicine for HF patients. Entresto is a twice-a-day medicine that reduces the strain on the failing heart 4,5.

Medicine 75

Medicine Trials Cardiology Production 75

The Pharma Data

NOVEMBER 4, 2020

Food and Drug Administration and European Medicine Agency as a potential therapy for patients with AL amyloidosis. Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines.

Antibody 52

Antibody Containment Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 29, 2020

Presented at the ESC Congress 2020, the annual meeting of the European Society of Cardiology, the analysis evaluated the efficacy and tolerability of inclisiran on top of a maximally tolerated dose of statins, in two studies of more than 2,300 patients (of which 1,164 were on inclisiran) from the Phase III trials.

Medicine 52

Medicine Containment Trials Production 52

The Pharma Data

JANUARY 12, 2021

Dosing is underway in Phase 3 trials of ULTOMIRIS in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), ALXN2060 (AG10) in ATTR cardiomyopathy in Japan , CAEL -101 in AL amyloidosis and ALXN2040 in paroxysmal nocturnal hemoglobinuria (PNH) patients with extravascular hemolysis (EVH).

Containment 52

Containment Development Sales Production 52

The Pharma Data

OCTOBER 14, 2020

Michael Felker, MD, MHS, FACC, FAHA, FHFSA is Professor of Medicine with tenure in the Division of Cardiology at Duke University School of Medicine. He is Director of Cardiovascular Research at the Duke Clinical Research Institute and Vice-Chief for Clinical Research in the Division of Cardiology.

Cardiology 40

Cardiology Clinical Trials Clinical Trials Medicine 40

The Pharma Data

NOVEMBER 4, 2020

Progressed European regulatory review and commercial preparations : Continued to support regulatory review of VASCEPA by the European Medicines Agency (EMA) with the expectation of an early 2021 approval of VASCEPA for commercial sale in Europe. FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM.

Sales 40

Sales Production Cardiology Marketing 40